{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T23:43:06Z","timestamp":1790725386788,"version":"4.1.0"},"reference-count":181,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T00:00:00Z","timestamp":1787788800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T00:00:00Z","timestamp":1787788800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Cardiol"],"DOI":"10.1038\/s41569-026-01336-1","type":"journal-article","created":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T12:13:19Z","timestamp":1787832799000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Dyslipidaemia and hepatic steatosis: mechanisms and implications for lipid-lowering therapy"],"prefix":"10.1038","author":[{"given":"Maurizio","family":"Averna","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9663-300X","authenticated-orcid":false,"given":"M. Mahmood","family":"Hussain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6081-1257","authenticated-orcid":false,"given":"Giuseppe Danilo","family":"Norata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,27]]},"reference":[{"key":"1336_CR1","doi-asserted-by":"publisher","DOI":"10.1002\/edm2.70132","volume":"8","author":"DM Miller","year":"2025","unstructured":"Miller, D. M., McCauley, K. F. & Dunham-Snary, K. J. Metabolic dysfunction-associated steatotic liver disease (MASLD): mechanisms, clinical implications and therapeutic advances. Endocrinol. Diabetes Metab. 8, e70132 (2025).","journal-title":"Endocrinol. Diabetes Metab."},{"key":"1336_CR2","doi-asserted-by":"publisher","first-page":"85","DOI":"10.7326\/0003-4819-90-1-85","volume":"90","author":"WB Kannel","year":"1979","unstructured":"Kannel, W. B., Castelli, W. P. & Gordon, T. Cholesterol in the prediction of atherosclerotic disease. New perspectives based on the Framingham study. Ann. Intern. Med. 90, 85\u201391 (1979).","journal-title":"Ann. Intern. Med."},{"key":"1336_CR3","doi-asserted-by":"publisher","first-page":"2459","DOI":"10.1093\/eurheartj\/ehx144","volume":"38","author":"BA Ference","year":"2017","unstructured":"Ference, B. A. et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur. Heart J. 38, 2459\u20132472 (2017).","journal-title":"Eur. Heart J."},{"key":"1336_CR4","doi-asserted-by":"publisher","first-page":"e168","DOI":"10.1161\/ATV.0000000000000153","volume":"42","author":"PB Duell","year":"2022","unstructured":"Duell, P. B. et al. Nonalcoholic fatty liver disease and cardiovascular risk: a scientific statement from the American Heart Association. Arterioscler. Thromb. Vasc. Biol. 42, e168\u2013e185 (2022).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"1336_CR5","unstructured":"Global Burden of Cardiovascular Diseases and Risks 2023 Collaborators. Global, regional, and national burden of cardiovascular diseases and risk factors in 204 countries and territories, 1990-2023. J. Am. Coll. Cardiol. 86, 2167\u20132243 (2025)."},{"key":"1336_CR6","unstructured":"World Health Federation. World Health Report 2023: Confronting the World\u2019s Number One Killer https:\/\/world-heart-federation.org\/wp-content\/uploads\/World-Heart-Report-2023.pdf (WHF, 2023)."},{"key":"1336_CR7","doi-asserted-by":"crossref","unstructured":"Taubert, K. A. & Smith, S. C. in Global Challenges in Cardiovascular Prevention in Populations with Low Socioeconomic Status (eds Romero, T. et al.) 243\u2013261 (Springer, 2025).","DOI":"10.1007\/978-3-031-79051-5_13"},{"key":"1336_CR8","doi-asserted-by":"publisher","first-page":"e674","DOI":"10.1161\/CIR.0000000000000395","volume":"133","author":"RL Sacco","year":"2016","unstructured":"Sacco, R. L. et al. The Heart of 25 by 25: achieving the goal of reducing global and regional premature deaths from cardiovascular diseases and stroke: a modeling study from the American Heart Association and World Heart Federation. Circulation 133, e674\u2013e690 (2016).","journal-title":"Circulation"},{"key":"1336_CR9","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1056\/NEJMoa2206916","volume":"389","author":"C Global Cardiovascular Risk","year":"2023","unstructured":"Global Cardiovascular Risk, C. et al. Global effect of modifiable risk factors on cardiovascular disease and mortality. N. Engl. J. Med. 389, 1273\u20131285 (2023).","journal-title":"N. Engl. J. Med."},{"key":"1336_CR10","unstructured":"World Health Organization. The Global Health Observatory. who.int https:\/\/www.who.int\/data\/gho\/data\/indicators\/indicator-details\/GHO\/chol_05 (2021)."},{"key":"1336_CR11","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1016\/S0140-6736(04)17018-9","volume":"364","author":"S Yusuf","year":"2004","unstructured":"Yusuf, S. et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 364, 937\u2013952 (2004).","journal-title":"Lancet"},{"key":"1336_CR12","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/s41586-020-2338-1","volume":"582","author":"NCD Risk Factor Collaboration.","year":"2020","unstructured":"NCD Risk Factor Collaboration. Repositioning of the global epicentre of non-optimal cholesterol. Nature 582, 73\u201377 (2020).","journal-title":"Nature"},{"key":"1336_CR13","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1136\/gutjnl-2023-330595","volume":"73","author":"G Targher","year":"2024","unstructured":"Targher, G., Byrne, C. D. & Tilg, H. MASLD: a systemic metabolic disorder with cardiovascular and malignant complications. Gut 73, 691\u2013702 (2024).","journal-title":"Gut"},{"key":"1336_CR14","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1097\/HEP.0000000000000286","volume":"77","author":"HS Ahmed","year":"2023","unstructured":"Ahmed, H. S. et al. The association between hepatic steatosis and incident cardiovascular disease, cancer, and all-cause mortality in a US multicohort study. Hepatology 77, 2063\u20132072 (2023).","journal-title":"Hepatology"},{"key":"1336_CR15","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2024.1380506","volume":"11","author":"S Fazio","year":"2024","unstructured":"Fazio, S., Mercurio, V., Tibullo, L., Fazio, V. & Affuso, F. Insulin resistance\/hyperinsulinemia: an important cardiovascular risk factor that has long been underestimated. Front. Cardiovasc. Med. 11, 1380506 https:\/\/doi.org\/10.3389\/fcvm.2024.1380506 (2024).","journal-title":"Front. Cardiovasc. Med."},{"key":"1336_CR16","doi-asserted-by":"publisher","DOI":"10.1172\/JCI186420","author":"GR Steinberg","year":"2025","unstructured":"Steinberg, G. R., Carpentier, A. C. & Wang, D. MASH: the nexus of metabolism, inflammation, and fibrosis. J. Clin. Invest. https:\/\/doi.org\/10.1172\/JCI186420 (2025).","journal-title":"J. Clin. Invest."},{"key":"1336_CR17","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1002\/hep.30664","volume":"70","author":"AJ Sanyal","year":"2019","unstructured":"Sanyal, A. J. et al. The natural history of advanced fibrosis due to nonalcoholic steatohepatitis: data from the simtuzumab trials. Hepatology 70, 1913\u20131927 (2019).","journal-title":"Hepatology"},{"key":"1336_CR18","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1186\/s12933-024-02434-5","volume":"23","author":"H Zheng","year":"2024","unstructured":"Zheng, H., Sechi, L. A., Navarese, E. P., Casu, G. & Vidili, G. Metabolic dysfunction-associated steatotic liver disease and cardiovascular risk: a comprehensive review. Cardiovasc. Diabetol. 23, 346 (2024).","journal-title":"Cardiovasc. Diabetol."},{"key":"1336_CR19","doi-asserted-by":"publisher","first-page":"101185","DOI":"10.1016\/j.jhepr.2024.101185","volume":"6","author":"F Carli","year":"2024","unstructured":"Carli, F., Della Pepa, G., Sabatini, S., Vidal Puig, A. & Gastaldelli, A. Lipid metabolism in MASLD and MASH: from mechanism to the clinic. JHEP Rep. 6, 101185 (2024).","journal-title":"JHEP Rep."},{"key":"1336_CR20","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1002\/hep.29466","volume":"67","author":"C Estes","year":"2018","unstructured":"Estes, C., Razavi, H., Loomba, R., Younossi, Z. & Sanyal, A. J. Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease. Hepatology 67, 123\u2013133 (2018).","journal-title":"Hepatology"},{"key":"1336_CR21","doi-asserted-by":"publisher","DOI":"10.1007\/s11892-018-1101-6","volume":"18","author":"P Bjornstad","year":"2018","unstructured":"Bjornstad, P. & Eckel, R. H. Pathogenesis of lipid disorders in insulin resistance: a brief review. Curr. Diabetes Rep. 18, 127 (2018).","journal-title":"Curr. Diabetes Rep."},{"key":"1336_CR22","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1016\/j.cmet.2012.03.004","volume":"15","author":"RV Farese Jr.","year":"2012","unstructured":"Farese, R. V. Jr., Zechner, R., Newgard, C. B. & Walther, T. C. The problem of establishing relationships between hepatic steatosis and hepatic insulin resistance. Cell Metab. 15, 570\u2013573 (2012).","journal-title":"Cell Metab."},{"key":"1336_CR23","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1194\/jlr.R083451","volume":"59","author":"A Sirwi","year":"2018","unstructured":"Sirwi, A. & Hussain, M. M. Lipid transfer proteins in the assembly of apoB-containing lipoproteins. J. Lipid Res. 59, 1094\u20131102 (2018).","journal-title":"J. Lipid Res."},{"key":"1336_CR24","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1146\/annurev-nutr-062222-020716","volume":"44","author":"J Boren","year":"2024","unstructured":"Boren, J., Taskinen, M. R. & Packard, C. J. Biosynthesis and metabolism of apoB-containing lipoproteins. Annu. Rev. Nutr. 44, 179\u2013204 (2024).","journal-title":"Annu. Rev. Nutr."},{"key":"1336_CR25","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1161\/CIRCRESAHA.123.323284","volume":"134","author":"W van Zwol","year":"2024","unstructured":"van Zwol, W., van de Sluis, B., Ginsberg, H. N. & Kuivenhoven, J. A. VLDL biogenesis and secretion: it takes a village. Circ. Res. 134, 226\u2013244 (2024).","journal-title":"Circ. Res."},{"key":"1336_CR26","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1016\/j.bbalip.2011.09.009","volume":"1821","author":"LK Cole","year":"2012","unstructured":"Cole, L. K., Vance, J. E. & Vance, D. E. Phosphatidylcholine biosynthesis and lipoprotein metabolism. Biochim. Biophys. Acta 1821, 754\u2013761 (2012).","journal-title":"Biochim. Biophys. Acta"},{"key":"1336_CR27","doi-asserted-by":"publisher","first-page":"E1183","DOI":"10.1152\/ajpendo.90899.2008","volume":"296","author":"J Iqbal","year":"2009","unstructured":"Iqbal, J. & Hussain, M. M. Intestinal lipid absorption. Am. J. Physiol. Endocrinol. Metab. 296, E1183\u2013E1194 (2009).","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"1336_CR28","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1161\/ATVBAHA.111.241497","volume":"32","author":"R Lehner","year":"2012","unstructured":"Lehner, R., Lian, J. & Quiroga, A. D. Lumenal lipid metabolism: implications for lipoprotein assembly. Arterioscler. Thromb. Vasc. Biol. 32, 1087\u20131093 (2012).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"1336_CR29","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1194\/jlr.R200014-JLR200","volume":"44","author":"MM Hussain","year":"2003","unstructured":"Hussain, M. M., Shi, J. & Dreizen, P. Microsomal triglyceride transfer protein and its role in apolipoprotein B-lipoprotein assembly. J. Lipid Res. 44, 22\u201332 (2003).","journal-title":"J. Lipid Res."},{"key":"1336_CR30","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1016\/S0022-2275(20)30267-4","volume":"42","author":"JP Segrest","year":"2001","unstructured":"Segrest, J. P., Jones, M. K., De Loof, H. & Dashti, N. Structure of apolipoprotein B-100 in low density lipoproteins. J. Lipid Res. 42, 1346\u20131367 (2001).","journal-title":"J. Lipid Res."},{"key":"1336_CR31","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/0009-3084(85)90068-4","volume":"38","author":"JR Wetterau","year":"1985","unstructured":"Wetterau, J. R. & Zilversmit, D. B. Purification and characterization of microsomal triglyceride and cholesteryl ester transfer protein from bovine liver microsomes. Chem. Phys. Lipids 38, 205\u2013222 (1985).","journal-title":"Chem. Phys. Lipids"},{"key":"1336_CR32","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1038\/353448a0","volume":"3536","author":"RJ Pease","year":"1991","unstructured":"Pease, R. J., Harrison, G. B. & Scott, J. Cotranslational insertion of apolipoprotein B into the inner leaflet of the endoplasmic reticulum. Nature 3536, 448\u2013450 (1991).","journal-title":"Nature"},{"key":"1336_CR33","doi-asserted-by":"publisher","first-page":"1912","DOI":"10.1053\/j.gastro.2020.11.040","volume":"160","author":"C Bredefeld","year":"2021","unstructured":"Bredefeld, C., Peretti, N., Hussain, M. M. & Medical Advisory, P. New classification and management of abetalipoproteinemia and related disorders. Gastroenterology 160, 1912\u20131916 (2021).","journal-title":"Gastroenterology"},{"key":"1336_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacl.2022.08.009","author":"C Bredefeld","year":"2022","unstructured":"Bredefeld, C. et al. Guidance for the diagnosis and treatment of hypolipidemia disorders. J. Clin. Lipidol. https:\/\/doi.org\/10.1016\/j.jacl.2022.08.009 (2022).","journal-title":"J. Clin. Lipidol."},{"key":"1336_CR35","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1097\/MOL.0000000000000983","volume":"36","author":"A Visser","year":"2025","unstructured":"Visser, A., Hussain, M. M. & Kuivenhoven, J. A. The intracellular chylomicron highway: novel insights into chylomicron biosynthesis, trafficking, and secretion. Curr. Opin. Lipidol. 36, 145\u2013152 (2025).","journal-title":"Curr. Opin. Lipidol."},{"key":"1336_CR36","doi-asserted-by":"publisher","first-page":"101146","DOI":"10.1016\/j.molmet.2020.101146","volume":"50","author":"DY Vos","year":"2021","unstructured":"Vos, D. Y. & van de Sluis, B. Function of the endolysosomal network in cholesterol homeostasis and metabolic-associated fatty liver disease (MAFLD). Mol. Metab. 50, 101146 (2021).","journal-title":"Mol. Metab."},{"key":"1336_CR37","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1016\/j.jhep.2016.01.025","volume":"64","author":"L Scheja","year":"2016","unstructured":"Scheja, L. & Heeren, J. Metabolic interplay between white, beige, brown adipocytes and the liver. J. Hepatol. 64, 1176\u20131186 (2016).","journal-title":"J. Hepatol."},{"key":"1336_CR38","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1097\/MOL.0000000000000663","volume":"31","author":"FK Welty","year":"2020","unstructured":"Welty, F. K. Hypobetalipoproteinemia and abetalipoproteinemia: liver disease and cardiovascular disease. Curr. Opin. Lipidol. 31, 49\u201355 (2020).","journal-title":"Curr. Opin. Lipidol."},{"key":"1336_CR39","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1016\/j.jhep.2014.05.023","volume":"61","author":"M Di Filippo","year":"2014","unstructured":"Di Filippo, M. et al. Homozygous MTTP and APOB mutations may lead to hepatic steatosis and fibrosis despite metabolic differences in congenital hypocholesterolemia. J. Hepatol. 61, 891\u2013902 (2014).","journal-title":"J. Hepatol."},{"key":"1336_CR40","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1161\/CIRCULATIONAHA.113.001292","volume":"129","author":"DJ Rader","year":"2014","unstructured":"Rader, D. J. & Kastelein, J. J. Lomitapide and mipomersen: two first-in-class drugs for reducing low-density lipoprotein cholesterol in patients with homozygous familial hypercholesterolemia. Circulation 129, 1022\u20131032 (2014).","journal-title":"Circulation"},{"key":"1336_CR41","doi-asserted-by":"publisher","first-page":"100257","DOI":"10.1016\/j.jlr.2022.100257","volume":"63","author":"N Anaganti","year":"2022","unstructured":"Anaganti, N., Chattopadhyay, A., Poirier, J. T. & Hussain, M. M. Generation of hepatoma cell lines deficient in microsomal triglyceride transfer protein. J. Lipid Res. 63, 100257 (2022).","journal-title":"J. Lipid Res."},{"key":"1336_CR42","doi-asserted-by":"publisher","first-page":"1774","DOI":"10.1073\/pnas.92.5.1774","volume":"92","author":"RV Farese Jr.","year":"1995","unstructured":"Farese, R. V. Jr., Ruland, S. L., Flynn, L. M., Stokowski, R. P. & Young, S. G. Knockout of the mouse apolipoprotein B gene results in embryonic lethality in homozygotes and protection against diet-induced hypercholesterolemia in heterozygotes. Proc. Natl Acad. Sci. USA 92, 1774\u20131778 (1995).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1336_CR43","doi-asserted-by":"publisher","first-page":"8686","DOI":"10.1073\/pnas.95.15.8686","volume":"95","author":"M Raabe","year":"1998","unstructured":"Raabe, M. et al. Knockout of the abetalipoproteinemia gene in mice: reduced lipoprotein secretion in heterozygotes and embryonic lethality in homozygotes. Proc. Natl Acad. Sci. USA 95, 8686\u20138691 (1998).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1336_CR44","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1172\/JCI6576","volume":"103","author":"M Raabe","year":"1999","unstructured":"Raabe, M. et al. Analysis of the role of microsomal triglyceride transfer protein in the liver of tissue-specific knockout mice. J. Clin. Invest. 103, 1287\u20131298 (1999).","journal-title":"J. Clin. Invest."},{"key":"1336_CR45","doi-asserted-by":"publisher","first-page":"14372","DOI":"10.1074\/jbc.M113.459602","volume":"288","author":"J Josekutty","year":"2013","unstructured":"Josekutty, J., Iqbal, J., Iwawaki, T., Kohno, K. & Hussain, M. M. Microsomal triglyceride transfer protein inhibition induces endoplasmic reticulum stress and increases gene transcription via Ire1\u03b1\/cJun to enhance plasma ALT\/AST. J. Biol. Chem. 288, 14372\u201314383 (2013).","journal-title":"J. Biol. Chem."},{"key":"1336_CR46","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1038\/ng.2901","volume":"46","author":"J Kozlitina","year":"2014","unstructured":"Kozlitina, J. et al. Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease. Nat. Genet. 46, 352\u2013356 (2014).","journal-title":"Nat. Genet."},{"key":"1336_CR47","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1097\/MOL.0000000000000930","volume":"35","author":"J Liu","year":"2024","unstructured":"Liu, J., Ginsberg, H. N. & Reyes-Soffer, G. Basic and translational evidence supporting the role of TM6SF2 in VLDL metabolism. Curr. Opin. Lipidol. 35, 157\u2013161 (2024).","journal-title":"Curr. Opin. Lipidol."},{"key":"1336_CR48","doi-asserted-by":"publisher","first-page":"102048","DOI":"10.1016\/j.molmet.2024.102048","volume":"90","author":"H Wang","year":"2024","unstructured":"Wang, H. et al. FITM2 deficiency results in ER lipid accumulation, ER stress, and reduced apolipoprotein B lipidation and VLDL triglyceride secretion in vitro and in mouse liver. Mol. Metab. 90, 102048 (2024).","journal-title":"Mol. Metab."},{"key":"1336_CR49","doi-asserted-by":"publisher","first-page":"eadh5207","DOI":"10.1126\/science.adh5207","volume":"381","author":"W Dai","year":"2023","unstructured":"Dai, W. et al. Intracellular tPA-PAI-1 interaction determines VLDL assembly in hepatocytes. Science 381, eadh5207 (2023).","journal-title":"Science"},{"key":"1336_CR50","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-46102-4","volume":"15","author":"JH Thierer","year":"2024","unstructured":"Thierer, J. H. et al. Pla2g12b drives expansion of triglyceride-rich lipoproteins. Nat. Commun. 15, 2095 (2024).","journal-title":"Nat. Commun."},{"key":"1336_CR51","doi-asserted-by":"publisher","first-page":"11494","DOI":"10.1021\/bi0349930","volume":"42","author":"M Rouault","year":"2003","unstructured":"Rouault, M., Bollinger, J. G., Lazdunski, M., Gelb, M. H. & Lambeau, G. Novel mammalian group XII secreted phospholipase A2 lacking enzymatic activity. Biochemistry 42, 11494\u201311503 (2003).","journal-title":"Biochemistry"},{"key":"1336_CR52","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1016\/j.bbalip.2006.07.011","volume":"1761","author":"RH Schaloske","year":"2006","unstructured":"Schaloske, R. H. & Dennis, E. A. The phospholipase A2 superfamily and its group numbering system. Biochim. Biophys. Acta 1761, 1246\u20131259 (2006).","journal-title":"Biochim. Biophys. Acta"},{"key":"1336_CR53","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1002\/hep.24066","volume":"53","author":"M Guan","year":"2011","unstructured":"Guan, M., Qu, L., Tan, W., Chen, L. & Wong, C. W. Hepatocyte nuclear factor-4 alpha regulates liver triglyceride metabolism in part through secreted phospholipase A2 GXIIB. Hepatology 53, 458\u2013466 (2011).","journal-title":"Hepatology"},{"key":"1336_CR54","doi-asserted-by":"publisher","first-page":"101712","DOI":"10.1016\/j.jcmgh.2025.101712","volume":"20","author":"B Prakash","year":"2025","unstructured":"Prakash, B. et al. Cysteine 129 in Pla2g12b is critical for intestinal and hepatic lipoprotein secretion in mice. Cell. Mol. Gastroenterol. Hepatol. 20, 101712 (2025).","journal-title":"Cell. Mol. Gastroenterol. Hepatol."},{"key":"1336_CR55","doi-asserted-by":"publisher","first-page":"200","DOI":"10.5551\/jat.11.200","volume":"11","author":"S Takahashi","year":"2004","unstructured":"Takahashi, S. et al. The very low-density lipoprotein (VLDL) receptor: characterization and functions as a peripheral lipoprotein receptor. J. Atheroscler. Thromb. 11, 200\u2013208 (2004).","journal-title":"J. Atheroscler. Thromb."},{"key":"1336_CR56","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1002\/hep.26126","volume":"57","author":"H Jo","year":"2013","unstructured":"Jo, H. et al. Endoplasmic reticulum stress induces hepatic steatosis via increased expression of the hepatic very low-density lipoprotein receptor. Hepatology 57, 1366\u20131377 (2013).","journal-title":"Hepatology"},{"key":"1336_CR57","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.1194\/jlr.M041988","volume":"55","author":"Y Gao","year":"2014","unstructured":"Gao, Y. et al. Upregulation of hepatic VLDLR via PPAR\u03b1 is required for the triglyceride-lowering effect of fenofibrate. J. Lipid Res. 55, 1622\u20131633 (2014).","journal-title":"J. Lipid Res."},{"key":"1336_CR58","doi-asserted-by":"publisher","DOI":"10.3390\/biology11050792","author":"S Todisco","year":"2022","unstructured":"Todisco, S. et al. PPAR alpha as a metabolic modulator of the liver: role in the pathogenesis of nonalcoholic steatohepatitis (NASH). Biology https:\/\/doi.org\/10.3390\/biology11050792 (2022).","journal-title":"Biology"},{"key":"1336_CR59","doi-asserted-by":"publisher","first-page":"166286","DOI":"10.1016\/j.bbadis.2021.166286","volume":"1868","author":"M Dille","year":"2022","unstructured":"Dille, M. et al. Long-term adjustment of hepatic lipid metabolism after chronic stress and the role of FGF21. Biochim. Biophys. Acta 1868, 166286 (2022).","journal-title":"Biochim. Biophys. Acta"},{"key":"1336_CR60","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1007\/s00535-013-0758-5","volume":"48","author":"Y Kawano","year":"2013","unstructured":"Kawano, Y. & Cohen, D. E. Mechanisms of hepatic triglyceride accumulation in non-alcoholic fatty liver disease. J. Gastroenterol. 48, 434\u2013441 (2013).","journal-title":"J. Gastroenterol."},{"key":"1336_CR61","doi-asserted-by":"publisher","first-page":"5810","DOI":"10.1073\/pnas.86.15.5810","volume":"86","author":"RC Kowal","year":"1989","unstructured":"Kowal, R. C., Herz, J., Goldstein, J. L., Esser, V. & Brown, M. S. Low density lipoprotein receptor-related protein mediates uptake of cholesteryl esters derived from apoprotein E-enriched lipoproteins. Proc. Natl Acad. Sci. USA 86, 5810\u20135814 (1989).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1336_CR62","doi-asserted-by":"publisher","first-page":"9674","DOI":"10.1074\/jbc.RA118.001952","volume":"293","author":"AN Hamlin","year":"2018","unstructured":"Hamlin, A. N. et al. Low-density lipoprotein receptor-related protein-1 dysfunction synergizes with dietary cholesterol to accelerate steatohepatitis progression. J. Biol. Chem. 293, 9674\u20139684 (2018).","journal-title":"J. Biol. Chem."},{"key":"1336_CR63","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.ebiom.2016.04.002","volume":"7","author":"Y Ding","year":"2016","unstructured":"Ding, Y., Xian, X., Holland, W. L., Tsai, S. & Herz, J. Low-density lipoprotein receptor-related protein-1 protects against hepatic insulin resistance and hepatic steatosis. eBioMedicine 7, 135\u2013145 (2016).","journal-title":"eBioMedicine"},{"key":"1336_CR64","doi-asserted-by":"publisher","first-page":"100012","DOI":"10.1194\/jlr.RA120001141","volume":"62","author":"A Jaeschke","year":"2021","unstructured":"Jaeschke, A. et al. Mutation in the distal NPxY motif of LRP1 alleviates dietary cholesterol-induced dyslipidemia and tissue inflammation. J. Lipid Res. 62, 100012 (2021).","journal-title":"J. Lipid Res."},{"key":"1336_CR65","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0030668","volume":"7","author":"V Bieghs","year":"2012","unstructured":"Bieghs, V. et al. LDL receptor knock-out mice are a physiological model particularly vulnerable to study the onset of inflammation in non-alcoholic fatty liver disease. PLoS ONE 7, e30668 (2012).","journal-title":"PLoS ONE"},{"key":"1336_CR66","doi-asserted-by":"publisher","first-page":"9037","DOI":"10.1074\/jbc.RA119.008094","volume":"294","author":"PF Lebeau","year":"2019","unstructured":"Lebeau, P. F. et al. Diet-induced hepatic steatosis abrogates cell-surface LDLR by inducing de novo PCSK9 expression in mice. J. Biol. Chem. 294, 9037\u20139047 (2019).","journal-title":"J. Biol. Chem."},{"key":"1336_CR67","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1080\/17446651.2023.2204932","volume":"18","author":"PK Gill","year":"2023","unstructured":"Gill, P. K. & Hegele, R. A. Low cholesterol states: clinical implications and management. Expert Rev. Endocrinol. Metab. 18, 241\u2013253 (2023).","journal-title":"Expert Rev. Endocrinol. Metab."},{"key":"1336_CR68","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.2174\/1381612827666210216151645","volume":"27","author":"P Anagnostis","year":"2021","unstructured":"Anagnostis, P. et al. Prevalence of non-coronary heart disease in patients with familial hypercholesterolemia: an analysis from the HELLAS-FH. Curr. Pharm. Des. 27, 2537\u20132544 (2021).","journal-title":"Curr. Pharm. Des."},{"key":"1336_CR69","first-page":"404","volume":"34","author":"E Cholongitas","year":"2021","unstructured":"Cholongitas, E. et al. Epidemiology of nonalcoholic fatty liver disease in Europe: a systematic review and meta-analysis. Ann. Gastroenterol. 34, 404\u2013414 (2021).","journal-title":"Ann. Gastroenterol."},{"key":"1336_CR70","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s13059-025-03518-5","volume":"26","author":"R Chen","year":"2025","unstructured":"Chen, R. et al. Trans-ancestral rare variant association study with machine learning-based phenotyping for metabolic dysfunction-associated steatotic liver disease. Genome Biol. 26, 50 (2025).","journal-title":"Genome Biol."},{"key":"1336_CR71","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1111\/1751-2980.70011","volume":"26","author":"E Theocharidou","year":"2025","unstructured":"Theocharidou, E. & Gossios, T. Effect of statins and PCSK9 inhibition on metabolic dysfunction-associated steatotic liver disease. J. Dig. Dis. 26, 392\u2013397 (2025).","journal-title":"J. Dig. Dis."},{"key":"1336_CR72","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1210\/jc.2009-0141","volume":"94","author":"SG Lakoski","year":"2009","unstructured":"Lakoski, S. G., Lagace, T. A., Cohen, J. C., Horton, J. D. & Hobbs, H. H. Genetic and metabolic determinants of plasma PCSK9 levels. J. Clin. Endocrinol. Metab. 94, 2537\u20132543 (2009).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1336_CR73","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1080\/07853890.2016.1188328","volume":"48","author":"M Ruscica","year":"2016","unstructured":"Ruscica, M. et al. Liver fat accumulation is associated with circulating PCSK9. Ann. Med. 48, 384\u2013391 (2016).","journal-title":"Ann. Med."},{"key":"1336_CR74","doi-asserted-by":"publisher","DOI":"10.1186\/s12944-025-02831-z","author":"KH Yeh","year":"2025","unstructured":"Yeh, K. H., Hsu, L. A., Tran, N. Y., Wu, S. & Ko, Y. L. High circulating PCSK9 concentration is associated with increased and sex-specific risks of metabolic disease, diabetes mellitus, MASLD, and long-term mortality in a Taiwanese population. Lipids Health Dis. https:\/\/doi.org\/10.1186\/s12944-025-02831-z (2025).","journal-title":"Lipids Health Dis."},{"key":"1336_CR75","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.clinbiochem.2020.01.003","volume":"77","author":"M Paquette","year":"2020","unstructured":"Paquette, M. et al. Circulating PCSK9 is associated with liver biomarkers and hepatic steatosis. Clin. Biochem. 77, 20\u201325 (2020).","journal-title":"Clin. Biochem."},{"key":"1336_CR76","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.atherosclerosis.2018.09.008","volume":"278","author":"M Wargny","year":"2018","unstructured":"Wargny, M. et al. Circulating PCSK9 levels are not associated with the severity of hepatic steatosis and NASH in a high-risk population. Atherosclerosis 278, 82\u201390 (2018).","journal-title":"Atherosclerosis"},{"key":"1336_CR77","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1016\/j.soard.2024.01.017","volume":"20","author":"D Castellano-Castillo","year":"2024","unstructured":"Castellano-Castillo, D. et al. The role of PCSK9 in metabolic dysfunction-associated steatotic liver disease and its impact on bariatric surgery outcomes. Surg. Obes. Relat. Dis. 20, 652\u2013659 (2024).","journal-title":"Surg. Obes. Relat. Dis."},{"key":"1336_CR78","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/j.jhepr.2019.10.009","volume":"1","author":"PF Lebeau","year":"2019","unstructured":"Lebeau, P. F. et al. Pcsk9 knockout exacerbates diet-induced non-alcoholic steatohepatitis, fibrosis and liver injury in mice. JHEP Rep. 1, 418\u2013429 (2019).","journal-title":"JHEP Rep."},{"key":"1336_CR79","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1161\/ATVBAHA.115.306032","volume":"35","author":"A Demers","year":"2015","unstructured":"Demers, A. et al. PCSK9 induces CD36 degradation and affects long-chain fatty acid uptake and triglyceride metabolism in adipocytes and in mouse liver. Arterioscler. Thromb. Vasc. Biol. 35, 2517\u20132525 (2015).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"1336_CR80","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1210\/en.2015-1866","volume":"157","author":"CG Wilson","year":"2016","unstructured":"Wilson, C. G. et al. Hepatocyte-specific disruption of CD36 attenuates fatty liver and improves insulin sensitivity in HFD-fed mice. Endocrinology 157, 570\u2013585 (2016).","journal-title":"Endocrinology"},{"key":"1336_CR81","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1002\/hep4.1858","volume":"6","author":"GN Ioannou","year":"2022","unstructured":"Ioannou, G. N. et al. Pcsk9 deletion promotes murine nonalcoholic steatohepatitis and hepatic carcinogenesis: role of cholesterol. Hepatol. Commun. 6, 780\u2013794 (2022).","journal-title":"Hepatol. Commun."},{"key":"1336_CR82","doi-asserted-by":"publisher","first-page":"1870","DOI":"10.1177\/2047487317724342","volume":"24","author":"A Baragetti","year":"2017","unstructured":"Baragetti, A. et al. PCSK9 deficiency results in increased ectopic fat accumulation in experimental models and in humans. Eur. J. Prev. Cardiol. 24, 1870\u20131877 (2017).","journal-title":"Eur. J. Prev. Cardiol."},{"key":"1336_CR83","doi-asserted-by":"publisher","first-page":"3078","DOI":"10.1093\/eurheartj\/ehab431","volume":"42","author":"L Da Dalt","year":"2021","unstructured":"Da Dalt, L. et al. PCSK9 deficiency rewires heart metabolism and drives heart failure with preserved ejection fraction. Eur. Heart J. 42, 3078\u20133090 (2021).","journal-title":"Eur. Heart J."},{"key":"1336_CR84","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1001\/jamacardio.2020.5341","volume":"6","author":"A Rimbert","year":"2021","unstructured":"Rimbert, A., Smati, S., Dijk, W., Le May, C. & Cariou, B. Genetic inhibition of PCSK9 and liver function. JAMA Cardiol. 6, 353\u2013354 (2021).","journal-title":"JAMA Cardiol."},{"key":"1336_CR85","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1111\/liv.14711","volume":"41","author":"S Grimaudo","year":"2021","unstructured":"Grimaudo, S. et al. PCSK9 rs11591147 R46L loss-of-function variant protects against liver damage in individuals with NAFLD. Liver Int. 41, 321\u2013332 (2021).","journal-title":"Liver Int."},{"key":"1336_CR86","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1093\/eurheartj\/ehy357","volume":"40","author":"L Da Dalt","year":"2019","unstructured":"Da Dalt, L. et al. PCSK9 deficiency reduces insulin secretion and promotes glucose intolerance: the role of the low-density lipoprotein receptor. Eur. Heart J. 40, 357\u2013368 (2019).","journal-title":"Eur. Heart J."},{"key":"1336_CR87","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.nbd.2014.08.025","volume":"72","author":"Y Huang","year":"2014","unstructured":"Huang, Y. & Mahley, R. W. Apolipoprotein E: structure and function in lipid metabolism, neurobiology, and Alzheimer\u2019s diseases. Neurobiol. Dis. 72, 3\u201312 (2014).","journal-title":"Neurobiol. Dis."},{"key":"1336_CR88","doi-asserted-by":"publisher","first-page":"117601","DOI":"10.1016\/j.lfs.2020.117601","volume":"252","author":"W Lu","year":"2020","unstructured":"Lu, W. et al. ApoE deficiency promotes non-alcoholic fatty liver disease in mice via impeding AMPK\/mTOR mediated autophagy. Life Sci. 252, 117601 (2020).","journal-title":"Life Sci."},{"key":"1336_CR89","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1172\/JCI0215593","volume":"109","author":"JD Horton","year":"2002","unstructured":"Horton, J. D., Goldstein, J. L. & Brown, M. S. SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J. Clin. Invest. 109, 1125\u20131131 (2002).","journal-title":"J. Clin. Invest."},{"key":"1336_CR90","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1161\/CIRCRESAHA.115.304378","volume":"115","author":"J Zhang","year":"2014","unstructured":"Zhang, J. et al. Cholesterol esters (CE) derived from hepatic sterol O-acyltransferase 2 (SOAT2) are associated with more atherosclerosis than CE from intestinal SOAT2. Circ. Res. 115, 826\u2013833 (2014).","journal-title":"Circ. Res."},{"key":"1336_CR91","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1073\/pnas.0336398100","volume":"100","author":"EL Willner","year":"2003","unstructured":"Willner, E. L. et al. Deficiency of acyl CoA:cholesterol acyltransferase 2 prevents atherosclerosis in apolipoprotein E-deficient mice. Proc. Natl Acad. Sci. USA 100, 1262\u20131267 (2003).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1336_CR92","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1111\/joim.13450","volume":"292","author":"C Pramfalk","year":"2022","unstructured":"Pramfalk, C. et al. Soat2 ties cholesterol metabolism to beta-oxidation and glucose tolerance in male mice. J. Intern. Med. 292, 296\u2013307 (2022).","journal-title":"J. Intern. Med."},{"key":"1336_CR93","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1056\/NEJMoa2309000","volume":"390","author":"SA Harrison","year":"2024","unstructured":"Harrison, S. A. et al. A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis. N. Engl. J. Med. 390, 497\u2013509 (2024).","journal-title":"N. Engl. J. Med."},{"key":"1336_CR94","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1016\/j.tips.2024.08.009","volume":"45","author":"NF Brisnovali","year":"2024","unstructured":"Brisnovali, N. F., Haney, C. & Goedeke, L. Rezdiffra\u2122 (resmetirom): a THR-\u03b2 agonist for non-alcoholic steatohepatitis. Trends Pharmacol. Sci. 45, 1081\u20131082 (2024).","journal-title":"Trends Pharmacol. Sci."},{"key":"1336_CR95","doi-asserted-by":"publisher","first-page":"155331","DOI":"10.1016\/j.metabol.2022.155331","volume":"137","author":"S Rajan","year":"2022","unstructured":"Rajan, S. et al. Microsomal triglyceride transfer protein regulates intracellular lipolysis in adipocytes independent of its lipid transfer activity. Metabolism 137, 155331 (2022).","journal-title":"Metabolism"},{"key":"1336_CR96","doi-asserted-by":"publisher","first-page":"101549","DOI":"10.1016\/j.jhepr.2025.101549","volume":"7","author":"S Rajan","year":"2025","unstructured":"Rajan, S. et al. Adipose microsomal triglyceride transfer protein deficiency protects against hepatic steatosis by upregulating PPAR\u03b1 activity. JHEP Rep. 7, 101549 (2025).","journal-title":"JHEP Rep."},{"key":"1336_CR97","doi-asserted-by":"publisher","first-page":"101177","DOI":"10.1016\/j.jbc.2021.101177","volume":"297","author":"D Susan-Resiga","year":"2021","unstructured":"Susan-Resiga, D. et al. Asialoglycoprotein receptor 1 is a novel PCSK9-independent ligand of liver LDLR cleaved by furin. J. Biol. Chem. 297, 101177 (2021).","journal-title":"J. Biol. Chem."},{"key":"1336_CR98","doi-asserted-by":"publisher","first-page":"2131","DOI":"10.1056\/NEJMoa1508419","volume":"374","author":"P Nioi","year":"2016","unstructured":"Nioi, P. et al. Variant ASGR1 associated with a reduced risk of coronary artery disease. N. Engl. J. Med. 374, 2131\u20132141 (2016).","journal-title":"N. Engl. J. Med."},{"key":"1336_CR99","doi-asserted-by":"publisher","first-page":"2428","DOI":"10.1161\/ATVBAHA.124.321076","volume":"44","author":"Y Zhang","year":"2024","unstructured":"Zhang, Y. et al. ASGR1 deficiency inhibits atherosclerosis in Western diet-fed ApoE\u2212\/\u2212 mice by regulating lipoprotein metabolism and promoting cholesterol efflux. Arterioscler. Thromb. Vasc. Biol. 44, 2428\u20132449 (2024).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"1336_CR100","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1186\/s12933-024-02507-5","volume":"23","author":"M Svecla","year":"2024","unstructured":"Svecla, M. et al. ASGR1 deficiency improves atherosclerosis but alters liver metabolism in ApoE\u2212\/\u2212 mice. Cardiovasc. Diabetol. 23, 428 (2024).","journal-title":"Cardiovasc. Diabetol."},{"key":"1336_CR101","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s12933-023-02099-6","volume":"23","author":"M Svecla","year":"2024","unstructured":"Svecla, M. et al. ASGR1 deficiency diverts lipids toward adipose tissue but results in liver damage during obesity. Cardiovasc. Diabetol. 23, 42 (2024).","journal-title":"Cardiovasc. Diabetol."},{"key":"1336_CR102","doi-asserted-by":"publisher","first-page":"31285","DOI":"10.1074\/jbc.272.50.31285","volume":"272","author":"ZS Ji","year":"1997","unstructured":"Ji, Z. S., Dichek, H. L., Miranda, R. D. & Mahley, R. W. Heparan sulfate proteoglycans participate in hepatic lipaseand apolipoprotein E-mediated binding and uptake of plasma lipoproteins, including high density lipoproteins. J. Biol. Chem. 272, 31285\u201331292 (1997).","journal-title":"J. Biol. Chem."},{"key":"1336_CR103","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1172\/JCI29154","volume":"117","author":"JM MacArthur","year":"2007","unstructured":"MacArthur, J. M. et al. Liver heparan sulfate proteoglycans mediate clearance of triglyceride-rich lipoproteins independently of LDL receptor family members. J. Clin. Invest. 117, 153\u2013164 (2007).","journal-title":"J. Clin. Invest."},{"key":"1336_CR104","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1038\/nrgastro.2013.182","volume":"10","author":"QM Anstee","year":"2013","unstructured":"Anstee, Q. M. & Day, C. P. The genetics of NAFLD. Nat. Rev. Gastroenterol. Hepatol. 10, 645\u2013655 (2013).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"1336_CR105","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1056\/NEJMra011775","volume":"346","author":"P Angulo","year":"2002","unstructured":"Angulo, P. Nonalcoholic fatty liver disease. N. Engl. J. Med. 346, 1221\u20131231 (2002).","journal-title":"N. Engl. J. Med."},{"key":"1336_CR106","doi-asserted-by":"publisher","first-page":"14281","DOI":"10.1074\/jbc.270.24.14281","volume":"270","author":"B Ricci","year":"1995","unstructured":"Ricci, B. et al. A 30-amino acid truncation of the microsomal triglyceride transfer protein large subunit disrupts its interaction with protein disulfide-isomerase and causes abetalipoproteinemia. J. Biol. Chem. 270, 14281\u201314285 (1995).","journal-title":"J. Biol. Chem."},{"key":"1336_CR107","doi-asserted-by":"publisher","first-page":"17251","DOI":"10.1073\/pnas.1903029116","volume":"116","author":"EI Biterova","year":"2019","unstructured":"Biterova, E. I. et al. The crystal structure of human microsomal triglyceride transfer protein. Proc. Natl Acad. Sci. USA 116, 17251\u201317260 (2019).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1336_CR108","doi-asserted-by":"publisher","first-page":"105726","DOI":"10.1016\/j.jbc.2024.105726","volume":"300","author":"N Anaganti","year":"2024","unstructured":"Anaganti, N. et al. Bulky hydrophobic side chains in the \u03b21-sandwich of microsomal triglyceride transfer protein are critical for the transfer of both triglycerides and phospholipids. J. Biol. Chem. 300, 105726 (2024).","journal-title":"J. Biol. Chem."},{"key":"1336_CR109","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1194\/jlr.M031658","volume":"54","author":"I Khatun","year":"2013","unstructured":"Khatun, I., Walsh, M. T. & Hussain, M. M. Loss of both phospholipid and triglyceride transfer activities of microsomal triglyceride transfer protein in abetalipoproteinemia. J. Lipid Res. 54, 1541\u20131549 (2013).","journal-title":"J. Lipid Res."},{"key":"1336_CR110","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1161\/CIRCGENETICS.115.001106","volume":"8","author":"MT Walsh","year":"2015","unstructured":"Walsh, M. T. et al. Novel abetalipoproteinemia missense mutation highlights the importance of the N-terminal \u03b2-barrel in microsomal triglyceride transfer protein function. Circ. Cardiovasc. Genet. 8, 677\u2013687 (2015).","journal-title":"Circ. Cardiovasc. Genet."},{"key":"1336_CR111","doi-asserted-by":"publisher","first-page":"100725","DOI":"10.1016\/j.jlr.2024.100725","volume":"66","author":"S Valmiki","year":"2025","unstructured":"Valmiki, S., Bredefeld, C. & Hussain, M. M. A novel mutation, Ile344Asn, in microsomal triglyceride transfer protein abolishes binding to protein disulfide isomerase. J. Lipid Res. 66, 100725 (2025).","journal-title":"J. Lipid Res."},{"key":"1336_CR112","doi-asserted-by":"publisher","first-page":"e19","DOI":"10.1016\/j.atherosclerosis.2007.05.003","volume":"195","author":"P Tarugi","year":"2007","unstructured":"Tarugi, P. et al. Molecular diagnosis of hypobetalipoproteinemia: an ENID review. Atherosclerosis 195, e19\u2013e27 (2007).","journal-title":"Atherosclerosis"},{"key":"1336_CR113","first-page":"1080","volume":"13","author":"TW Lou","year":"2025","unstructured":"Lou, T. W., Ren, T. Y. & Fan, J. G. Current and emerging issues in familial hypobetalipoproteinemia-related steatotic liver diseases. J. Clin. Transl. Hepatol. 13, 1080\u20131091 (2025).","journal-title":"J. Clin. Transl. Hepatol."},{"key":"1336_CR114","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-39998-2","volume":"9","author":"S Pelusi","year":"2019","unstructured":"Pelusi, S. et al. Rare pathogenic variants predispose to hepatocellular carcinoma in nonalcoholic fatty liver disease. Sci. Rep. 9, 3682 (2019).","journal-title":"Sci. Rep."},{"key":"1336_CR115","doi-asserted-by":"publisher","first-page":"2021","DOI":"10.1161\/ATVBAHA.112.301101","volume":"33","author":"AB Cefalu","year":"2013","unstructured":"Cefalu, A. B. et al. A novel APOB mutation identified by exome sequencing cosegregates with steatosis, liver cancer, and hypocholesterolemia. Arterioscler. Thromb. Vasc. Biol. 33, 2021\u20132025 (2013).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"1336_CR116","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.atherosclerosis.2009.01.037","volume":"206","author":"D Noto","year":"2009","unstructured":"Noto, D. et al. Familial hypobetalipoproteinemia due to apolipoprotein B R463W mutation causes intestinal fat accumulation and low postprandial lipemia. Atherosclerosis 206, 193\u2013198 (2009).","journal-title":"Atherosclerosis"},{"key":"1336_CR117","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21041439","author":"J Musialik","year":"2020","unstructured":"Musialik, J. et al. A rare mutation in the APOB gene associated with neurological manifestations in familial hypobetalipoproteinemia. Int. J. Mol. Sci. https:\/\/doi.org\/10.3390\/ijms21041439 (2020).","journal-title":"Int. J. Mol. Sci."},{"key":"1336_CR118","volume":"14","author":"E Bjornsson","year":"2021","unstructured":"Bjornsson, E. et al. Lifelong reduction in LDL (low-density lipoprotein) cholesterol due to a gain-of-function mutation in LDLR. Circulation 14, e003029 (2021).","journal-title":"Circulation"},{"key":"1336_CR119","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1053\/j.gastro.2020.12.023","volume":"160","author":"O Jamialahmadi","year":"2021","unstructured":"Jamialahmadi, O. et al. Exome-wide association study on alanine aminotransferase identifies sequence variants in the GPAM and APOE associated with fatty liver disease. Gastroenterology 160, 1634\u20131646 (2021).","journal-title":"Gastroenterology"},{"key":"1336_CR120","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s12944-022-01699-7","volume":"21","author":"Y Liu","year":"2022","unstructured":"Liu, Y. et al. Alcohol-dependent downregulation of apolipoprotein H exacerbates fatty liver and gut microbiota dysbiosis in mice. Lipids Health Dis. 21, 89 (2022).","journal-title":"Lipids Health Dis."},{"key":"1336_CR121","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1038\/ng.257","volume":"40","author":"S Romeo","year":"2008","unstructured":"Romeo, S. et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat. Genet. 40, 1461\u20131465 (2008).","journal-title":"Nat. Genet."},{"key":"1336_CR122","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1002\/hep.27490","volume":"61","author":"P Dongiovanni","year":"2015","unstructured":"Dongiovanni, P. et al. Transmembrane 6 superfamily member 2 gene variant disentangles nonalcoholic steatohepatitis from cardiovascular disease. Hepatology 61, 506\u2013514 (2015).","journal-title":"Hepatology"},{"key":"1336_CR123","doi-asserted-by":"publisher","first-page":"4737","DOI":"10.1093\/eurheartj\/ehaf606","volume":"46","author":"CM Ballantyne","year":"2025","unstructured":"Ballantyne, C. M. & Norata, G. D. The evolving landscape of targets for lipid lowering: from molecular mechanisms to translational implications. Eur. Heart J. 46, 4737\u20134750 (2025).","journal-title":"Eur. Heart J."},{"key":"1336_CR124","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1093\/eurheartj\/eht549","volume":"36","author":"RD Santos","year":"2015","unstructured":"Santos, R. D. et al. Long-term efficacy and safety of mipomersen in patients with familial hypercholesterolaemia: 2-year interim results of an open-label extension. Eur. Heart J. 36, 566\u2013575 (2015).","journal-title":"Eur. Heart J."},{"key":"1336_CR125","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1016\/j.jacl.2014.08.002","volume":"8","author":"N Hashemi","year":"2014","unstructured":"Hashemi, N. et al. Liver histology during mipomersen therapy for severe hypercholesterolemia. J. Clin. Lipidol. 8, 606\u2013611 (2014).","journal-title":"J. Clin. Lipidol."},{"key":"1336_CR126","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1111\/liv.15497","volume":"43","author":"D Larrey","year":"2023","unstructured":"Larrey, D., D\u2019Erasmo, L., O\u2019Brien, S. & Arca, M. Italian Working Group on Lomitapide. Long-term hepatic safety of lomitapide in homozygous familial hypercholesterolaemia. Liver Int. 43, 413\u2013423 (2023).","journal-title":"Liver Int."},{"key":"1336_CR127","first-page":"1164","volume":"19","author":"D Tramontano","year":"2025","unstructured":"Tramontano, D. et al. Lomitapide-induced fatty liver is a reversible condition: evidence from a case of familial chylomicronemia syndrome. J. Clin. Lipidol. 19, 1164\u20131170 (2025).","journal-title":"J. Clin. Lipidol."},{"key":"1336_CR128","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s12920-019-0536-1","volume":"12","author":"D Margerie","year":"2019","unstructured":"Margerie, D. et al. Hepatic transcriptomic signatures of statin treatment are associated with impaired glucose homeostasis in severely obese patients. BMC Med. Genom. 12, 80 (2019).","journal-title":"BMC Med. Genom."},{"key":"1336_CR129","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1111\/joim.20032","volume":"297","author":"O Ahmed","year":"2025","unstructured":"Ahmed, O. et al. Statin-associated regulation of hepatic PNPLA3 in patients without known liver disease. J. Intern. Med. 297, 47\u201359 (2025).","journal-title":"J. Intern. Med."},{"key":"1336_CR130","doi-asserted-by":"publisher","first-page":"e1367","DOI":"10.1210\/clinem\/dgae546","volume":"110","author":"B Feng","year":"2025","unstructured":"Feng, B. et al. Statin use and development and progression of nonalcoholic fatty liver disease based on ultrasonography. J. Clin. Endocrinol. Metab. 110, e1367\u2013e1376 (2025).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1336_CR131","doi-asserted-by":"publisher","DOI":"10.1136\/bmjgast-2024-001404","author":"AD Schreiner","year":"2024","unstructured":"Schreiner, A. D. et al. Statin prescriptions and progression of advanced fibrosis risk in primary care patients with MASLD. BMJ Open Gastroenterol. https:\/\/doi.org\/10.1136\/bmjgast-2024-001404 (2024).","journal-title":"BMJ Open Gastroenterol."},{"key":"1336_CR132","doi-asserted-by":"publisher","first-page":"104392","DOI":"10.1016\/j.ebiom.2022.104392","volume":"87","author":"I Ayada","year":"2023","unstructured":"Ayada, I. et al. Dissecting the multifaceted impact of statin use on fatty liver disease: a multidimensional study. eBioMedicine 87, 104392 (2023).","journal-title":"eBioMedicine"},{"key":"1336_CR133","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1016\/j.jhep.2015.05.006","volume":"63","author":"P Dongiovanni","year":"2015","unstructured":"Dongiovanni, P. et al. Statin use and non-alcoholic steatohepatitis in at risk individuals. J. Hepatol. 63, 705\u2013712 (2015).","journal-title":"J. Hepatol."},{"key":"1336_CR134","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.20222","volume":"6","author":"MS Vell","year":"2023","unstructured":"Vell, M. S. et al. Association of statin use with risk of liver disease, hepatocellular carcinoma, and liver-related mortality. JAMA Netw. Open 6, e2320222 (2023).","journal-title":"JAMA Netw. Open"},{"key":"1336_CR135","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25136938","author":"E Butera","year":"2024","unstructured":"Butera, E. et al. Exploring the role of bempedoic acid in metabolic dysfunction associated steatotic liver disease: actual evidence and future perspectives. Int. J. Mol. Sci. https:\/\/doi.org\/10.3390\/ijms25136938 (2024).","journal-title":"Int. J. Mol. Sci."},{"key":"1336_CR136","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1016\/j.cmet.2022.05.004","volume":"34","author":"MR Morrow","year":"2022","unstructured":"Morrow, M. R. et al. Inhibition of ATP-citrate lyase improves NASH, liver fibrosis, and dyslipidemia. Cell Metab. 34, 919\u2013936 (2022).","journal-title":"Cell Metab."},{"key":"1336_CR137","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1161\/ATVBAHA.116.308963","volume":"37","author":"JP Samsoondar","year":"2017","unstructured":"Samsoondar, J. P. et al. Prevention of diet-induced metabolic dysregulation, inflammation, and atherosclerosis in Ldlr\u2212\/\u2212 mice by treatment with the ATP-citrate lyase inhibitor bempedoic acid. Arterioscler. Thromb. Vasc. Biol. 37, 647\u2013656 (2017).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"1336_CR138","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.1194\/jlr.M035212","volume":"54","author":"S Filippov","year":"2013","unstructured":"Filippov, S. et al. ETC-1002 regulates immune response, leukocyte homing, and adipose tissue inflammation via LKB1-dependent activation of macrophage AMPK. J. Lipid Res. 54, 2095\u20132108 (2013).","journal-title":"J. Lipid Res."},{"key":"1336_CR139","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2025.12.018","author":"C Papa","year":"2026","unstructured":"Papa, C. et al. Bempedoic acid directly binds and activates PPAR\u03b1. Cell Metab. https:\/\/doi.org\/10.1016\/j.cmet.2025.12.018 (2026).","journal-title":"Cell Metab."},{"key":"1336_CR140","doi-asserted-by":"publisher","DOI":"10.1172\/JCI141513","author":"Y He","year":"2021","unstructured":"He, Y. et al. Neutrophil-to-hepatocyte communication via LDLR-dependent miR-223-enriched extracellular vesicle transfer ameliorates nonalcoholic steatohepatitis. J. Clin. Invest. https:\/\/doi.org\/10.1172\/JCI141513 (2021).","journal-title":"J. Clin. Invest."},{"key":"1336_CR141","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1016\/j.jacc.2021.07.056","volume":"78","author":"C Oleaga","year":"2021","unstructured":"Oleaga, C. et al. Hepatic sensing loop regulates PCSK9 secretion in response to inhibitory antibodies. J. Am. Coll. Cardiol. 78, 1437\u20131449 (2021).","journal-title":"J. Am. Coll. Cardiol."},{"key":"1336_CR142","doi-asserted-by":"publisher","first-page":"e17","DOI":"10.1093\/eurheartj\/ehz430","volume":"43","author":"P Guedeney","year":"2022","unstructured":"Guedeney, P. et al. Efficacy and safety of alirocumab and evolocumab: a systematic review and meta-analysis of randomized controlled trials. Eur. Heart J. 43, e17\u2013e25 (2022).","journal-title":"Eur. Heart J."},{"key":"1336_CR143","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1016\/j.jacc.2023.10.007","volume":"82","author":"RS Wright","year":"2023","unstructured":"Wright, R. S. et al. Safety and tolerability of inclisiran for treatment of hypercholesterolemia in 7 clinical trials. J. Am. Coll. Cardiol. 82, 2251\u20132261 (2023).","journal-title":"J. Am. Coll. Cardiol."},{"key":"1336_CR144","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","volume":"376","author":"MS Sabatine","year":"2017","unstructured":"Sabatine, M. S. et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N. Engl. J. Med. 376, 1713\u20131722 (2017).","journal-title":"N. Engl. J. Med."},{"key":"1336_CR145","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","volume":"379","author":"GG Schwartz","year":"2018","unstructured":"Schwartz, G. G. et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N. Engl. J. Med. 379, 2097\u20132107 (2018).","journal-title":"N. Engl. J. Med."},{"key":"1336_CR146","first-page":"1","volume":"9","author":"A Dimakopoulou","year":"2018","unstructured":"Dimakopoulou, A., Sfikas, G. & Athyros, V. PCSK9 administration ameliorates non alcoholic fatty disease in patients with heterozygous familial hyperlipidemia. Hell. J. Atheroscler. 9, 1\u20132 (2018).","journal-title":"Hell. J. Atheroscler."},{"key":"1336_CR147","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1016\/j.numecd.2020.11.009","volume":"31","author":"R Scicali","year":"2021","unstructured":"Scicali, R. et al. Analysis of steatosis biomarkers and inflammatory profile after adding on PCSK9 inhibitor treatment in familial hypercholesterolemia subjects with nonalcoholic fatty liver disease: a single lipid center real-world experience. Nutr. Metab. Cardiovasc. Dis. 31, 869\u2013879 (2021).","journal-title":"Nutr. Metab. Cardiovasc. Dis."},{"key":"1336_CR148","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.4254\/wjh.v12.i12.1258","volume":"12","author":"M Shafiq","year":"2020","unstructured":"Shafiq, M., Walmann, T., Nutalapati, V., Gibson, C. & Zafar, Y. Effects of proprotein convertase subtilisin\/kexin type-9 inhibitors on fatty liver. World J. Hepatol. 12, 1258\u20131266 (2020).","journal-title":"World J. Hepatol."},{"key":"1336_CR149","doi-asserted-by":"publisher","first-page":"983","DOI":"10.2174\/0929867323666160229114111","volume":"23","author":"A Pirillo","year":"2016","unstructured":"Pirillo, A., Catapano, A. L. & Norata, G. D. Niemann-Pick C1-Like 1 (NPC1L1) inhibition and cardiovascular diseases. Curr. Med. Chem. 23, 983\u2013999 (2016).","journal-title":"Curr. Med. Chem."},{"key":"1336_CR150","doi-asserted-by":"publisher","first-page":"1468476","DOI":"10.3389\/fendo.2024.1468476","volume":"15","author":"B Jiao","year":"2024","unstructured":"Jiao, B., Wang, B., Liu, B., Zhao, J. & Zhang, Y. Potential impact of ezetimibe on patients with NAFLD\/NASH: a meta-analysis of randomized controlled trials. Front. Endocrinol. 15, 1468476 (2024).","journal-title":"Front. Endocrinol."},{"key":"1336_CR151","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.2337\/db12-1397","volume":"62","author":"SM Chan","year":"2013","unstructured":"Chan, S. M. et al. Activation of PPAR\u03b1 ameliorates hepatic insulin resistance and steatosis in high fructose-fed mice despite increased endoplasmic reticulum stress. Diabetes 62, 2095\u20132105 (2013).","journal-title":"Diabetes"},{"key":"1336_CR152","doi-asserted-by":"publisher","first-page":"154798","DOI":"10.1016\/j.metabol.2021.154798","volume":"120","author":"J Yoo","year":"2021","unstructured":"Yoo, J., Jeong, I. K., Ahn, K. J., Chung, H. Y. & Hwang, Y. C. Fenofibrate, a PPAR\u03b1 agonist, reduces hepatic fat accumulation through the upregulation of TFEB-mediated lipophagy. Metabolism 120, 154798 (2021).","journal-title":"Metabolism"},{"key":"1336_CR153","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1016\/j.jacl.2018.08.003","volume":"12","author":"J Oscarsson","year":"2018","unstructured":"Oscarsson, J. et al. Effects of free omega-3 carboxylic acids and fenofibrate on liver fat content in patients with hypertriglyceridemia and non-alcoholic fatty liver disease: a double-blind, randomized, placebo-controlled study. J. Clin. Lipidol. 12, 1390\u20131403 (2018).","journal-title":"J. Clin. Lipidol."},{"key":"1336_CR154","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1111\/apt.16596","volume":"54","author":"A Nakajima","year":"2021","unstructured":"Nakajima, A. et al. Randomised clinical trial: Pemafibrate, a novel selective peroxisome proliferator-activated receptor alpha modulator (SPPARM\u03b1), versus placebo in patients with non-alcoholic fatty liver disease. Aliment. Pharmacol. Ther. 54, 1263\u20131277 (2021).","journal-title":"Aliment. Pharmacol. Ther."},{"key":"1336_CR155","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1001\/jamacardio.2023.2921","volume":"8","author":"RS Rosenson","year":"2023","unstructured":"Rosenson, R. S. et al. Longer-term efficacy and safety of evinacumab in patients with refractory hypercholesterolemia. JAMA Cardiol. 8, 1070\u20131076 (2023).","journal-title":"JAMA Cardiol."},{"key":"1336_CR156","doi-asserted-by":"publisher","first-page":"2422","DOI":"10.1093\/eurheartj\/ehae325","volume":"45","author":"D Gaudet","year":"2024","unstructured":"Gaudet, D. et al. Evinacumab in homozygous familial hypercholesterolaemia: long-term safety and efficacy. Eur. Heart J. 45, 2422\u20132434 (2024).","journal-title":"Eur. Heart J."},{"key":"1336_CR157","doi-asserted-by":"publisher","first-page":"e261","DOI":"10.1016\/j.jacl.2023.12.001","volume":"18","author":"A Zimerman","year":"2024","unstructured":"Zimerman, A. et al. Hepatic fat changes with antisense oligonucleotide therapy targeting ANGPTL3. J. Clin. Lipidol. 18, e261\u2013e268 (2024).","journal-title":"J. Clin. Lipidol."},{"key":"1336_CR158","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1016\/S0140-6736(25)00507-0","volume":"405","author":"KK Ray","year":"2025","unstructured":"Ray, K. K. et al. Durability and efficacy of solbinsiran, a GalNAc-conjugated siRNA targeting ANGPTL3, in adults with mixed dyslipidaemia (PROLONG-ANG3): a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet 405, 1594\u20131607 (2025).","journal-title":"Lancet"},{"key":"1336_CR159","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1016\/j.jhep.2011.08.018","volume":"56","author":"HM Parker","year":"2012","unstructured":"Parker, H. M. et al. Omega-3 supplementation and non-alcoholic fatty liver disease: a systematic review and meta-analysis. J. Hepatol. 56, 944\u2013951 (2012).","journal-title":"J. Hepatol."},{"key":"1336_CR160","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1812792","volume":"380","author":"DL Bhatt","year":"2019","unstructured":"Bhatt, D. L. et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N. Engl. J. Med. 380, 11\u201322 (2019).","journal-title":"N. Engl. J. Med."},{"key":"1336_CR161","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","volume":"384","author":"PN Newsome","year":"2021","unstructured":"Newsome, P. N. et al. A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis. N. Engl. J. Med. 384, 1113\u20131124 (2021).","journal-title":"N. Engl. J. Med."},{"key":"1336_CR162","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1056\/NEJMoa2401943","volume":"391","author":"R Loomba","year":"2024","unstructured":"Loomba, R. et al. Tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis. N. Engl. J. Med. 391, 299\u2013310 (2024).","journal-title":"N. Engl. J. Med."},{"key":"1336_CR163","doi-asserted-by":"publisher","first-page":"2180","DOI":"10.1016\/S0140-6736(18)32260-8","volume":"392","author":"JP Frias","year":"2018","unstructured":"Frias, J. P. et al. Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial. Lancet 392, 2180\u20132193 (2018).","journal-title":"Lancet"},{"key":"1336_CR164","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1016\/S2213-8587(22)00243-1","volume":"10","author":"HJL Heerspink","year":"2022","unstructured":"Heerspink, H. J. L. et al. Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial: post-hoc analysis of an open-label, randomised, phase 3 trial. Lancet Diabetes Endocrinol. 10, 774\u2013785 (2022).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"1336_CR165","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1016\/j.cmet.2018.03.001","volume":"27","author":"DJ Drucker","year":"2018","unstructured":"Drucker, D. J. Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cell Metab. 27, 740\u2013756 (2018).","journal-title":"Cell Metab."},{"key":"1336_CR166","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/j.molmet.2014.02.002","volume":"3","author":"S Kersten","year":"2014","unstructured":"Kersten, S. Integrated physiology and systems biology of PPAR\u03b1. Mol. Metab. 3, 354\u2013371 (2014).","journal-title":"Mol. Metab."},{"key":"1336_CR167","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.cell.2015.01.036","volume":"161","author":"JL Goldstein","year":"2015","unstructured":"Goldstein, J. L. & Brown, M. S. A century of cholesterol and coronaries: from plaques to genes to statins. Cell 161, 161\u2013172 (2015).","journal-title":"Cell"},{"key":"1336_CR168","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1002\/hep.25504","volume":"55","author":"I Khatun","year":"2012","unstructured":"Khatun, I. et al. Phospholipid transfer activity of MTP promotes assembly of phospholipid-rich apoB-containing lipoproteins and reduces plasma as well as hepatic lipids in mice. Hepatology 55, 1356\u20131368 (2012).","journal-title":"Hepatology"},{"key":"1336_CR169","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1097\/MOL.0b013e328312707c","volume":"19","author":"MM Hussain","year":"2008","unstructured":"Hussain, M. M. & Bakillah, A. New approaches to target microsomal triglyceride transfer protein. Curr. Opin. Lipidol. 19, 572\u2013578 (2008).","journal-title":"Curr. Opin. Lipidol."},{"key":"1336_CR170","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1038\/nm.3200","volume":"19","author":"J Soh","year":"2013","unstructured":"Soh, J., Iqbal, J., Queiroz, J., Fernandez-Hernando, C. & Hussain, M. M. MicroRNA-30c reduces hyperlipidemia and atherosclerosis by decreasing lipid synthesis and lipoprotein secretion. Nat. Med. 19, 892\u2013900 (2013).","journal-title":"Nat. Med."},{"key":"1336_CR171","doi-asserted-by":"publisher","first-page":"18397","DOI":"10.1074\/jbc.M116.728451","volume":"291","author":"S Irani","year":"2016","unstructured":"Irani, S. et al. MicroRNA-30c mimic mitigates hypercholesterolemia and atherosclerosis in mice. J. Biol. Chem. 291, 18397\u201318409 (2016).","journal-title":"J. Biol. Chem."},{"key":"1336_CR172","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1194\/jlr.M081299","volume":"59","author":"S Irani","year":"2018","unstructured":"Irani, S., Iqbal, J., Antoni, W. J., Ijaz, L. & Hussain, M. M. microRNA-30c reduces plasma cholesterol in homozygous familial hypercholesterolemic and type 2 diabetic mouse models. J. Lipid Res. 59, 144\u2013154 (2018).","journal-title":"J. Lipid Res."},{"key":"1336_CR173","doi-asserted-by":"publisher","first-page":"101813","DOI":"10.1016\/j.jbc.2022.101813","volume":"298","author":"PK Yadav","year":"2022","unstructured":"Yadav, P. K. et al. Novel efficacious microRNA-30c analogs reduce apolipoprotein B secretion in human hepatoma and primary hepatocyte cells. J. Biol. Chem. 298, 101813 (2022).","journal-title":"J. Biol. Chem."},{"key":"1336_CR174","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-026-72276-0","author":"B Prakash","year":"2026","unstructured":"Prakash, B. et al. MicroRNA-30c analog C2 decreases plasma cholesterol and atherosclerosis without causing liver injury in preclinical studies. Nat. Commun. https:\/\/doi.org\/10.1038\/s41467-026-72276-0 (2026).","journal-title":"Nat. Commun."},{"key":"1336_CR175","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1056\/NEJMoa2404147","volume":"391","author":"RS Rosenson","year":"2024","unstructured":"Rosenson, R. S. et al. Zodasiran, an RNAi therapeutic targeting ANGPTL3, for mixed hyperlipidemia. N. Engl. J. Med. 391, 913\u2013925 (2024).","journal-title":"N. Engl. J. Med."},{"key":"1336_CR176","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.gene.2012.03.050","volume":"500","author":"XE Peng","year":"2012","unstructured":"Peng, X. E., Wu, Y. L., Lu, Q. Q., Hu, Z. J. & Lin, X. Two genetic variants in FABP1 and susceptibility to non-alcohol fatty liver disease in a Chinese population. Gene 500, 54\u201358 (2012).","journal-title":"Gene"},{"key":"1336_CR177","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1507\/endocrj.EJ14-0052","volume":"61","author":"A Kitamoto","year":"2014","unstructured":"Kitamoto, A. et al. Association of polymorphisms in GCKR and TRIB1 with nonalcoholic fatty liver disease and metabolic syndrome traits. Endocr. J. 61, 683\u2013689 (2014).","journal-title":"Endocr. J."},{"key":"1336_CR178","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1053\/j.gastro.2016.01.032","volume":"150","author":"RM Mancina","year":"2016","unstructured":"Mancina, R. M. et al. The MBOAT7-TMC4 variant rs641738 increases risk of nonalcoholic fatty liver disease in individuals of European descent. Gastroenterology 150, 1219\u20131230 (2016).","journal-title":"Gastroenterology"},{"key":"1336_CR179","doi-asserted-by":"publisher","first-page":"412","DOI":"10.3350\/cmh.2018.0114","volume":"25","author":"P Phowthongkum","year":"2019","unstructured":"Phowthongkum, P., Suphapeetiporn, K. & Shotelersuk, V. Carnitine palmitoyl transferase 1A deficiency in an adult with recurrent severe steato hepatitis aggravated by high pathologic or physiologic demands: a roller-coaster for internists. Clin. Mol. Hepatol. 25, 412\u2013416 (2019).","journal-title":"Clin. Mol. Hepatol."},{"key":"1336_CR180","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1038\/ejhg.2012.256","volume":"21","author":"MC Janssen","year":"2013","unstructured":"Janssen, M. C. et al. Symptomatic lipid storage in carriers for the PNPLA2 gene. Eur. J. Hum. Genet. 21, 807\u2013815 (2013).","journal-title":"Eur. J. Hum. Genet."},{"key":"1336_CR181","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1001\/jamacardio.2019.2946","volume":"5","author":"E Bjornsson","year":"2020","unstructured":"Bjornsson, E. et al. Association of genetically predicted lipid levels with the extent of coronary atherosclerosis in Icelandic adults. JAMA Cardiol. 5, 13\u201320 (2020).","journal-title":"JAMA Cardiol."}],"container-title":["Nature Reviews Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41569-026-01336-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41569-026-01336-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41569-026-01336-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T13:02:42Z","timestamp":1787835762000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41569-026-01336-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,27]]},"references-count":181,"alternative-id":["1336"],"URL":"https:\/\/doi.org\/10.1038\/s41569-026-01336-1","relation":{},"ISSN":["1759-5002","1759-5010"],"issn-type":[{"value":"1759-5002","type":"print"},{"value":"1759-5010","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,27]]},"assertion":[{"value":"3 August 2026","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2026","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.A. has received consulting fees from Amarin, Arrowhead, Chiesi, Daiichi-Sankyo and MSD. G.D.N. has received grants\/consulting fees from Amgen, Daiichi-Sankyo, Meda Pharma, Menarini, MSD and Novartis. M.M.H. declares no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}